Richard Saynor wants to transform Sandoz Group AG into a world champion in copying leading-edge drugs, including anti-obesity and biological treatments, with the goal of bringing them to the masses.

Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.

Net sales were $6.9 billion in the first nine months of last year. Sandoz CEO Richard Saynor will remain at the helm of the business following the spin-off, which is scheduled to complete in the ...

What does that mean for Sandoz? A: In my 35 years in the industry ... A: The main difference between managing the unit before the split and being CEO of the standalone is not so much the ...

Basel, January 14, 2025 – Sandoz, the global leader in generic and biosimilar medicines, will confirm its strategic roadmap and highlight pipeline catalysts in a presentation today at the 43rd Annual ...

CEO Richard Saynor will highlight several recent ... we will continue to execute our purpose-driven strategy.” Sandoz uniquely positioned to benefit from market fundamentals, aims to lead ...

Sandoz Group AG (SDZNY), a Swiss generic and biosimilar medicines maker, Tuesday announced that the global generics and biosimilars ...

“Clearly this is a space that we’re intending to go after,” said Sandoz CEO Richard Saynor, when asked about GLP-1s on its ...